Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
500 mg | In stock | $ 42.00 | |
1 g | In stock | $ 66.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 50.00 |
Description | (−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats. |
In vivo | Diabetic rats were administered myrtenal (80 mg/kg bw) for a period of 28 days. Diabetic rats showed an increased the levels of plasma glucose, decreased the levels of plasma insulin, down-regulation of insulin receptor substrate 2 (IRS2), Akt and glucose transporter 2 (GLUT2) in liver and insulin receptor substrate 2 (IRS2), Akt and glucose transporter 4 (GLUT4) protein expression in skeletal muscle[1]. |
Synonyms | (1R)-(−)-Myrtenal |
Molecular Weight | 150.22 |
Formula | C10H14O |
CAS No. | 18486-69-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (199.71 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(−)-Myrtenal 18486-69-6 Others Akt hyperglycemia terpene inhibit GLUT2 Protein kinase B Inhibitor diabetic (1R)-(−)-Myrtenal (−) Myrtenal (?)-Myrtenal PKB (−)Myrtenal inhibitor